1. Home
  2. Live Updates
  3. Nicole ridgedale

Nicole Ridgedale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nicole ridgedale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nicole Ridgedale Today - Breaking & Trending Today

LexaGene's MiQLab Successfully Detects Mutant UK and South African COVID-19 Sequences


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
LexaGene’s MiQLab Successfully Detects Mutant UK and South African COVID-19 Sequences
LexaGene Holdings IncFebruary 10, 2021 GMT
BEVERLY, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) LexaGene Holdings, Inc., ( TSX-V: LXG; OTCQB: LXXGF ) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has successfully configured a MiQLab™ system to detect mutant sequences unique to the United Kingdom (UK, B.1.1.7)1 and South African (SA, B.1.351)2 variants of SARS-CoV-2, the pathogen that causes COVID-19.
ADVERTISEMENT
The UK variant, known to be more contagious and possibly deadlier, was first detected in the United States at the end of December and has now been identified in 33 states.3 Likewise, both the SA and Brazilian variants were first detected in the United States at the end of ....

South Africa , United States , United Kingdom , South African , Jay Adelaar , Lexagene Miqlab , Jack Regan , Nicole Ridgedale , Research Use , Venture Exchange Inc , Venture Exchange , Regulation Services Provider , Lexagene Holdings Inc , Gene Holdings , Emergency Use Authorization , Research Use Only , Corporate Marketing , Capital Markets , Corporate News , Diseases And Conditions , Products And Services , Covid 19 Pandemic , Lung Disease , Coronavirus Pandemic , New Products And Services , Infectious Diseases ,

LexaGene Starts FDA EUA Study for Point-of-Care COVID-19 Testing


[December 30, 2020]
LexaGene Starts FDA EUA Study for Point-of-Care COVID-19 Testing
Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has started a series of studies required by the FDA for Emergency Use Authorization (EUA) testing for its COVID-19 assay in a point-of-care (POC) environment using its fully automated MiQLab™ system.
Dr. Jack Regan, LexaGene’s CEO and Founder states, “I’m excited we have progressed to the point where we have started our FDA study. Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant ....

United States , United Kingdom , Jay Adelaar , Jack Regan , Nicole Ridgedale , Research Use , Lexagene Holdings Inc , Gene Holdings , Emergency Use Authorization , Polymerase Chain Reaction , Research Use Only , Corporate Marketing , Capital Markets , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , பலா ரீகந் , நிக்கோல் றிட்கேடலே , ஆராய்ச்சி பயன்பாடு , கீந் ஹோல்டிங்ஸ் , அவசரம் பயன்பாடு அங்கீகாரம் , ஆராய்ச்சி பயன்பாடு மட்டும் , பெருநிறுவன சந்தைப்படுத்தல் , மூலதனம் சந்தைகள் ,